Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription 20.03.2023 1 AJR Am J Roentgenol 1 Am J Clin Oncol 1 Am J Surg 6 BMC Cancer 3 Br J Cancer 1 Cancer 1 Cancer Cell 1 Cancer Sci 4 Clin Cancer Res 1 Clin Lung Cancer 1 Eur J Cancer 1 Eur J Cardiothorac Surg 1 Genes Chromosomes Cancer 3 Int J Cancer 1 Int J Oncol 2 J Cancer Res Clin Oncol 1 J Surg Oncol 1 J Thorac Cardiovasc Surg 4 Lung Cancer 3 Nat Med 1 Oncol Rep 1 Oncologist 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. ZIPPI ZD, Cortopassi IO, Johnson EM, McDermott S, et al
   U.S. Newspaper Coverage of Lung Cancer Screening from 2010 to 2022.
   AJR Am J Roentgenol. 2023 Mar 15. doi: 10.2214/AJR.23.29066.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

2. ASHA W, Koro S, Mayo Z, Yang K, et al
   Stereotactic Body Radiation Therapy for Sarcoma Pulmonary Metastases.
   Am J Clin Oncol. 2023 Mar 14. doi: 10.1097/COC.0000000000001000.
   PubMed         Abstract available
   
   

   
   Am J Surg

3. JAIN U, Jain B, Dee EC, Bajaj SS, et al
   Trends in location of death for individuals with metastatic lung cancer in the United States.
   Am J Surg. 2023 Feb 24:S0002-9610(23)00085-5. doi: 10.1016/j.amjsurg.2023.
   PubMed        
   
   

   
   BMC Cancer

4. ABEDIAN KALKHORAN H, Zwaveling J, Storm BN, van Laar SA, et al
   A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer.
   BMC Cancer. 2023;23:247.
   PubMed         Abstract available
   
   
5. HUANG J, Hu B, Yang Y, Liu H, et al
   Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma.
   BMC Cancer. 2023;23:241.
   PubMed         Abstract available
   
   
6. ITO M, Miyata Y, Kushitani K, Ueda D, et al
   Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
   BMC Cancer. 2023;23:248.
   PubMed         Abstract available
   
   
7. HUANG CT, Lin CA, Su TJ, Yang CY, et al
   Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
   BMC Cancer. 2023;23:234.
   PubMed         Abstract available
   
   
8. ZHANG Y, Kong FF, Zhu ZQ, Shan HX, et al
   Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy.
   BMC Cancer. 2023;23:225.
   PubMed         Abstract available
   
   
9. BATES KM, Vathiotis I, MacNeil T, Ahmed FS, et al
   Spatial characterization and quantification of CD40 expression across cancer types.
   BMC Cancer. 2023;23:220.
   PubMed         Abstract available
   
   

   
   Br J Cancer

10. JUSTE-LANAS Y, Diaz-Valdivia N, Llorente A, Ikemori R, et al
    3D collagen migration patterns reveal a SMAD3-dependent and TGF-beta1-independent mechanism of recruitment for tumour-associated fibroblasts in lung adenocarcinoma.
    Br J Cancer. 2023;128:967-981.
    PubMed         Abstract available
    
    
11. MARKHAM JF, Fellowes AP, Green T, Leal JL, et al
    Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq.
    Br J Cancer. 2023;128:1148-1154.
    PubMed         Abstract available
    
    
12. VALKO Z, Megyesfalvi Z, Schwendenwein A, Lang C, et al
    Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
    Br J Cancer. 2023 Mar 14. doi: 10.1038/s41416-023-02219.
    PubMed         Abstract available
    
    

    
    Cancer

13. BIRONZO P, Cani M, Jacobs F, Napoli VM, et al
    Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy.
    Cancer. 2023 Mar 11. doi: 10.1002/cncr.34731.
    PubMed         Abstract available
    
    

    
    Cancer Cell

14. KLEMENT JD, Redd PS, Lu C, Merting AD, et al
    Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment.
    Cancer Cell. 2023;41:620-636.
    PubMed         Abstract available
    
    

    
    Cancer Sci

15. SHIBAHARA D, Akanuma N, Kobayashi IS, Heo E, et al
    TIP60 is required for tumorigenesis in non-small cell lung cancer.
    Cancer Sci. 2023 Mar 14. doi: 10.1111/cas.15785.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

16. BRUNO R, Marchand M, Yoshida K, Chan P, et al
    Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
    Clin Cancer Res. 2023;29:1047-1055.
    PubMed         Abstract available
    
    
17. GRANT MJ, Aredo JV, Starrett JH, Stockhammer P, et al
    Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations.
    Clin Cancer Res. 2023 Mar 13:CCR-22-3497. doi: 10.1158/1078-0432.CCR-22-3497.
    PubMed         Abstract available
    
    
18. YU M, Ju L, Cao X
    Perioperative ctDNA-Based MRD Detection in NSCLC-Letter.
    Clin Cancer Res. 2023;29:1155.
    PubMed        
    
    
19. XIA L, Yang Y, Chen W, Liu L, et al
    Perioperative ctDNA-Based MRD Detection in NSCLC-Response.
    Clin Cancer Res. 2023;29:1156.
    PubMed        
    
    

    
    Clin Lung Cancer

20. BERNABE-CARO R, Chen Y, Dowlati A, Eason P, et al
    Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review.
    Clin Lung Cancer. 2023 Feb 8:S1525-7304(23)00017.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

21. NAKAMURA A, Yamaguchi O, Mori K, Miura K, et al
    Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
    Eur J Cancer. 2023;184:62-72.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

22. FOURDRAIN A, Thomas PA
    Metachronous ipsilateral lung cancer: reoperate if you can!
    Eur J Cardiothorac Surg. 2023;63:ezad093.
    PubMed        
    
    

    
    Genes Chromosomes Cancer

23. MICHAL M, Kravtsov O, Ross JS, Skanderova D, et al
    Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features.
    Genes Chromosomes Cancer. 2023;62:267-274.
    PubMed         Abstract available
    
    

    
    Int J Cancer

24. KRISTIANSEN MF, Mikkelsen RM, Kristiansdottir T, Andorsdottir G, et al
    Cancer survival in the Faroe Islands over the last 50 years compared to the other Nordic countries.
    Int J Cancer. 2023;152:2090-2098.
    PubMed         Abstract available
    
    
25. CHENG ES, Velentzis LS, Weber M, Steinberg J, et al
    Female reproductive and hormonal factors and lung cancer mortality among never-smokers: a prospective cohort study of 287 408 Chinese women.
    Int J Cancer. 2023 Mar 14. doi: 10.1002/ijc.34508.
    PubMed         Abstract available
    
    
26. CANNON-ALBRIGHT LA, Teerlink CC, Stevens J, Facelli JC, et al
    A rare FGF5 candidate variant (rs112475347) for predisposition to non-squamous, non-small-cell lung cancer.
    Int J Cancer. 2023 Mar 14. doi: 10.1002/ijc.34510.
    PubMed         Abstract available
    
    

    
    Int J Oncol

27. XUE T, Chen Y, Xu J, Du W, et al
    Cyclovirobuxine D inhibits growth and progression of non‑small cell lung cancer cells by suppressing the KIF11‑CDC25C‑CDK1‑CyclinB1 G(2)/M phase transition regulatory network and the NFkappaB/JNK signaling pathway.
    Int J Oncol. 2023;62:57.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

28. TO KKW, Cheung KM, Cho WCS
    Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment.
    J Cancer Res Clin Oncol. 2023 Mar 11. doi: 10.1007/s00432-023-04641.
    PubMed         Abstract available
    
    
29. KIM JS, Kim EJ, Jang JG, Hong KS, et al
    Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer: a single-center analysis of 10 years.
    J Cancer Res Clin Oncol. 2023 Mar 13. doi: 10.1007/s00432-023-04686.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

30. HANSDOTTER P, Scherman P, Nikberg M, Petersen SH, et al
    Treatment and survival of patients with metachronous colorectal lung metastases.
    J Surg Oncol. 2023;127:806-814.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

31. SHARGALL Y, Wiercioch W, Brunelli A, Murthy S, et al
    Joint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery guidelines for the prevention of cancer-associated venous thromboembolism in thoracic surgery.
    J Thorac Cardiovasc Surg. 2023;165:794-824.
    PubMed         Abstract available
    
    

    
    Lung Cancer

32. DAHER S, Zer A, Tschernichovsky R, Yacobi R, et al
    Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer.
    Lung Cancer. 2023;178:229-236.
    PubMed         Abstract available
    
    
33. AKAGI K, Yagishita S, Ohuchi M, Hayashi Y, et al
    Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2023;178:247-253.
    PubMed         Abstract available
    
    
34. SAKAMOTO M, Patil T
    MET alterations in advanced non-small cell lung cancer.
    Lung Cancer. 2023;178:254-268.
    PubMed         Abstract available
    
    
35. CAYUELA L, Gaeta AM, Lopez-Campos JL, Reinoso-Arija R, et al
    Age-period-cohort effect on lung cancer mortality in Spain, 1982-2021.
    Lung Cancer. 2023;178:269-276.
    PubMed         Abstract available
    
    

    
    Nat Med

36. CASCONE T, Leung CH, Weissferdt A, Pataer A, et al
    Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189.
    PubMed         Abstract available
    
    
37. CONROY M, Forde PM
    Advancing neoadjuvant immunotherapy for lung cancer.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-023-02246.
    PubMed        
    
    
38. ASSAF ZJF, Zou W, Fine AD, Socinski MA, et al
    A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-023-02226.
    PubMed         Abstract available
    
    

    
    Oncol Rep

39. WANG L, Feng H, Li D
    Effect of shRNA‑mediated knockdown EBF1 gene expression on the proliferation of lung cancer cell line A549 in vitro and in vivo.
    Oncol Rep. 2023;49:90.
    PubMed         Abstract available
    
    

    
    Oncologist

40. LI LX, Cappuzzo F, Matos I, Socinski MA, et al
    Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.
    Oncologist. 2023 Mar 11:oyad043. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

41. LEI F, Lee E, Shin J, Lee SY, et al
    Non-pharmacological interventions on anxiety and depression in lung cancer patients' informal caregivers: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0282887.
    PubMed         Abstract available
    
    
42. AMAYA-NIETO J, Torres G, Buitrago G
    Prevalence of lung cancer in Colombia and a new diagnostic algorithm using health administrative databases: A real-world evidence study.
    PLoS One. 2023;18:e0269079.
    PubMed         Abstract available
    
    
43. KWAK SH, Kim EK, Kim MH, Lee EH, et al
    Incidentally found resectable lung cancer with the usage of artificial intelligence on chest radiographs.
    PLoS One. 2023;18:e0281690.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: